Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 120Lymphoma 90Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Burkitt Lymphoma 31Leukemia 27Multiple Myeloma 26Lymphoma, Non-Hodgkin 26Lymphoma, Follicular 26Hodgkin Disease 24Lymphoma, Mantle-Cell 18Neoplasms 16Lymphoma, T-Cell, Peripheral 16Lymphoma, B-Cell 14Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, Large-Cell, Anaplastic 11Dendritic Cell Sarcoma, Interdigitating 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Neoplasms, Plasma Cell 7Neoplasm Metastasis 7Waldenstrom Macroglobulinemia 6Primary Myelofibrosis 6Lymphoma, T-Cell 6Immunoblastic Lymphadenopathy 6HIV Infections 5Graft vs Host Disease 5Blast Crisis 5

Interventions

Triptorelin Pamoate 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel × Prednisone × Clear all
NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
75 enrolled
Genitourinary

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

Data powered by HemOnc (CC BY 4.0) Colophon âš¡